International Journal of Antimicrobial Agents

Article	Citations
Increased antimicrobial resistance during the COVID-19 pandemic	279
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update	183
Different mutations in SARS-CoV-2 associate with severe and mild outcome	119
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study	78
Long-acting drugs and formulations for the treatment and prevention of HIV infection	71
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients	68
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial	64
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections	61
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli	60
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections	57
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance	55
Methylene blue inhibits replication of SARS-CoV-2 in vitro	54
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine	53
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infecti	52
Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level	47
High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade	46
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial	45
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin	40
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals	38
Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination	38
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital	38
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	37
Effect of antibiotics on the human microbiome: a systematic review	36
A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa	36
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis	36

Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review	35
Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis	34
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)	34
Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance	33
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections	33
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?	33
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa	33
Bacteriophage–antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model	32
Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns	32
Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies	32
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019	31
An insight into the implementation of the global action plan on antimicrobial resistance in the WHO African region: A roadmap for action	31
Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment	31
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19	31
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited	29
Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)	27
Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy	27
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care	27
RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae	27
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa	26
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid	26
Extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a ‘One Health’ study	26
Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas	26
A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial	25
Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: high prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea	25
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics	24
Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections	24
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance	23
Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing	23
Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study	23
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept	23
The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids	23
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study	23
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature	23
Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015–2019	23
Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae	22
Plasma medicine and wound management: Evaluation of the antibacterial efficacy of a medically certified cold atmospheric argon plasma jet	22
Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics	22
Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012–2016	22
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020	22
Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland	21
Management of Comorbidities in Treated HIV Infection: A Long Way to Go	21
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients	21
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects	20
Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results f	20
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs	20
Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998–2019	20
Therapeutic modalities and novel approaches in regenerative medicine for COVID-19	19
Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis	19
Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review	19

Antibiotic resistance in Enterobacter hormaechei	19
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-n	19
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices	19
Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives	19
Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016–2020)	19
Evaluation of area under the concentration–time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury	19
Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales	19
LPD-12: a promising lipopeptide to control COVID-19	18
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections	18
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactam	18
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond	18
Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study	18
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2	18
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes	18
A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting	18
Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli	18
Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC25	17
Passive immunization and its rebirth in the era of the COVID-19 pandemic	17
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome rank	17
Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance	17
Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales	17
Evaluation of early antibiotic use in patients with non‐severe COVID‐19 without bacterial infection	17
Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study	17
Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy	17
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review	16
Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients	16
In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens	16
Discovery of macrozones, new antimicrobial thiosemicarbazone-based azithromycin conjugates: design, synthesis and in vitro biological evaluation	16
Direct prediction of carbapenem-resistant, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluat	16
Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study	16
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics	16
Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study	16
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	15
Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review	15
Vertical transmission and kidney damage in newborns whose mothers had coronavirus disease 2019 during pregnancy	15
Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole	15
Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections	15
Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice	15
Ferric chloride induces ferroptosis in Pseudomonas aeruginosa and heals wound infection in a mouse model	15
Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii	15
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results	15
Macrolides from rare actinomycetes: Structures and bioactivities	15
Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models	14
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study	14
Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)	14
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence	14
Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration	14
Antibody-based strategies in HIV therapy	14
Preferences regarding antibiotic treatment and the role of antibiotic resistance: A discrete choice experiment	14
Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study	14
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)	14
Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines	14
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis	13
Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltr	13
Antimicrobial drug resistance mechanisms among Mollicutes	13
The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem‐resistant Acinetobacter baumannii isolates in Germany, 2010‐2019	13
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci	13
Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing	13
Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil	13
Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testing	13
Disruption of biofilms and killing of Burkholderia cenocepacia from cystic fibrosis lung using an antioxidant-antibiotic combination therapy	13
Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas ae	13
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based	13
Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea	13
Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia	13
Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae	13
LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring	13
Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia	13
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae	13
Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China	13
Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam	12
Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function	12
Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area	12
Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal	12
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria	12
Ampicillin triggers the release of Pal in toxic vesicles from Escherichia coli	12
Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital	12
Pattern and appropriateness of antibiotic prescriptions for upper respiratory tract infections in primary care paediatric patients	12
The dlt operon contributes to the resistance to chlorhexidine in Streptococcus mutans	12
A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression	12

Antimicrobial effect of auranofin against Acanthamoeba spp.	12
Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017–2018), and on clonal distribution of MRSA	12
Carriage of the mcr-9 and mcr-10 genes in clinical strains of the Enterobacter cloacae complex in China: a prevalence and molecular epidemiology study	12
The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo	12
Large-scale survey of parental antibiotic use for paediatric upper respiratory tract infections in China: implications for stewardship programmes and national policy	12
Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection	12
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes	12
Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience	12
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from	12
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy	12
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database	12
Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk	12
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance	12
One Health and Global Health View of Antimicrobial Susceptibility through the “Eye” of Aeromonas: Systematic Review and Meta-Analysis	11
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-ce	11
MRSA surveillance programmes worldwide: moving towards a harmonised international approach	11
Effect of iron chelation on anti-pseudomonal activity of doxycycline	11
Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain	11
Synergy with farnesol rejuvenates colistin activity against Colistin-resistant Gram-negative bacteria in vitro and in vivo	11
Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections	11
Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)	11
Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study)	11
Pharmacodynamics of ceftriaxone for the treatment of methicillin‐susceptible Staphylococcus aureus: is it a viable treatment option?	11
Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials	11
Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review	11
Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia	11
New options for bloodstream infections caused by colistin‐ or ceftazidime/avibactam‐resistant Klebsiella pneumoniae	11
In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam	11
USA300 (sequence type 8) has become a major clone of methicillin-resistant Staphylococcus aureus in northern Taiwan	10
Clinical characteristics, tolerance mechanisms, and molecular epidemiology of reduced susceptibility to chlorhexidine among Pseudomonas aeruginosa isolated from a teaching hospital in China	10
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease	10
Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria	10
Fructose-enabled killing of antibiotic-resistant Salmonella enteritidis by gentamicin: Insight from reprogramming metabolomics	10
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia	10
Dynamics of extended-spectrum cephalosporin-resistant Escherichia coli in pig farms: A longitudinal study	10
Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surve	10
Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012–2018	10
Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia	10
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel	10
Prevalence of the fimbrial operon mrkABCD, mrkA expression, biofilm formation and effect of biocides on biofilm formation in carbapenemase-producing Klebsiella pneumoniae isolates belonging or not bel	10
Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China	10
Insight into phylogenomic bias of bla or bla dissemination amongst carbapenem-resistant Pseudomonas aeruginosa	10
Clonal outbreak of NDM-1-producing Enterobacter hormaechei belonging to high-risk international clone ST78 with the coexistence of tmexCD2-toprJ2 and mcr-9 in China	10
Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model	9
Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria	9
Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection	9
Co-transfer of mcr-8 with blaNDM-1 or tmexCD1-toprJ1 by plasmid hybridisation	9
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteo	9
Implementation of a novel antimicrobial stewardship strategy for rural facilities utilising telehealth	9
Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance	9
Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report	9
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification	9
Emergence of a VIM-2-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa ST309 in South America: a comparative genomic analysis	9
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19	9
Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia	9
Comparative genome analysis of global and Russian strains of community-acquired methicillin-resistant Staphylococcus aureus ST22, a ‘Gaza clone’	9
High-level delafloxacin resistance through the combination of two different mechanisms in Staphylococcus aureus	9
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis	9
Systematic review and meta-analysis to explore optimal therapeutic range of vancomycin trough level for infected paediatric patients with Gram-positive pathogens to reduce mortality and nephrotoxicity	9
Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university ho	9
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections	9
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoni	9
Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review	9
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover cli	9
High prevalence of clonally related ST182 NDM-1-producing Enterobacter cloacae complex clinical isolates in Greece	9
The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan	9
Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis	9
Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision	9
Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study	9
Uncomplicated Streptococcal Bacteremia: The Era of Oral Antibiotic Step-down Therapy?	9
In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm	9
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid	8
Doxycycline as an Alternative to Azithromycin in Elderly Patients	8
In vitro activity of eravacycline and mechanisms of resistance in enterococci	8
NDM-5-producing carbapenem-resistant Klebsiella pneumoniae of sequence type 789 emerged as a threat for neonates: a multicentre, genome-based study	8
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study	8
Co-occurrence of mcr-2 and mcr-3 genes on chromosome of multidrug-resistant Escherichia coli isolated from healthy individuals in Thailand	8
Cefiderocol heteroresistance in Klebsiella pneumoniae is linked to mutations in the siderophore receptor cirA and β-lactamase activities	8
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)	8
In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections	8
Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients	8
Genomic characterisation of CC398 MRSA causing severe disease in Australia	8
Overexpression of mcr-1 disrupts cell envelope synthesis and causes the dysregulation of carbon metabolism, redox balance and nucleic acids	8
Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018	8
Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae	8
Advanced statistical methods and designs for clinical trials for COVID-19	8
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.	8
Controlling biofilm and virulence properties of Gram-positive bacteria by targeting wall teichoic acid and lipoteichoic acid	8
Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis	8
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex	8
Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of Clostridioides difficile Infection	8
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019–2020 Nati	8
Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections	8
Changes in the prevalence of pathogens causing hospital-acquired bacterial pneumonia and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity-score-matched study	8
Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients	8